Business Strategy and Development Partner in the Life Science Industry with over 30 years of experience in Pharma, Pharma Chemistry and Biotech.  

Hemastatx is committed to bringing innovation to patients with severe and underserved bleeding disorders. Our lead program, HMX-001, is a first-in-class antibody therapy designed to address the root cause of severe bleeding episodes in patients with von Willebrand factor (VWF) disorders.

Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. We developed a new generation of protease inhibitors with enhanced potency and safety, exhibiting all the qualities needed to become first-in-class drugs for the treatment of cancer, autoimmune diseases and bone diseases.